Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

Executive Summary

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Advertisement

Related Content

Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib
Bayer Confident It Can Cope With Patent Cliff Pain
Lilly/Loxo Deal Came Together Quickly
Bayer Still Confident Of Future Prospects Post-Xarelto
Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion
J&J's Apalutamide, Astellas/Pfizer's Xtandi On Par For Non-Metastatic Prostate Cancer
How The Prostate Cancer Market Will Look Over Next Decade
Bayer Shrugs Off Xofigo Sales Pressure From Study Halt
Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer
Bayer signs €50m deal for Orion's prostate cancer drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel